enVVeno Medical Corp (NVNO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, enVVeno Medical Corp (NVNO) has a cash flow conversion efficiency ratio of -0.149x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.39 Million) by net assets ($29.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NVNO market cap for the company's overall valuation and market capitalisation.
enVVeno Medical Corp - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how enVVeno Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
enVVeno Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enVVeno Medical Corp ranked by their cash flow conversion efficiency. See debt repayment capacity of enVVeno Medical Corp to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rathdowney Resources Ltd
V:RTH
|
0.013x |
|
hGears AG
XETRA:HGEA
|
-0.050x |
|
Worksport Ltd
NASDAQ:WKSP
|
-0.412x |
|
IMPRENDIROMA S.P.A.
F:Y37
|
N/A |
|
GD Culture Group Limited
NASDAQ:GDC
|
-23455.197x |
|
Horisont Energi AS
OL:HRGI
|
-3.104x |
|
Compodium International AB
ST:COMPDM
|
0.015x |
|
Euro Menkul Kiymet Yatirim Ortakligi AS
IS:EUYO
|
0.005x |
Annual Cash Flow Conversion Efficiency for enVVeno Medical Corp (2014–2024)
The table below shows the annual cash flow conversion efficiency of enVVeno Medical Corp from 2014 to 2024. View latest enVVeno Medical Corp stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $42.16 Million | $-16.84 Million | -0.399x | +2.15% |
| 2023-12-31 | $46.20 Million | $-18.86 Million | -0.408x | -1.21% |
| 2022-12-31 | $38.73 Million | $-15.62 Million | -0.403x | -85.22% |
| 2021-12-31 | $54.40 Million | $-11.85 Million | -0.218x | +79.87% |
| 2020-12-31 | $7.10 Million | $-7.68 Million | -1.082x | +81.84% |
| 2019-12-31 | $989.94K | $-5.90 Million | -5.956x | -90.84% |
| 2018-12-31 | $2.04 Million | $-6.36 Million | -3.121x | -542.63% |
| 2017-12-31 | $-5.96 Million | $-4.20 Million | 0.705x | -93.51% |
| 2016-12-31 | $-283.72K | $-3.08 Million | 10.872x | +858.52% |
| 2015-12-31 | $-1.78 Million | $-2.02 Million | 1.134x | +1874180.75% |
| 2014-12-31 | $-2.01 Million | $121.74 | 0.000x | -- |
About enVVeno Medical Corp
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in … Read more